Cyberonics, Inc. (CYBX)

1/125 in Health Care Equipment -(73.7 @ B+/B+)

CYBX

Need some drugs

An Icahn portfolio stock.

RSI 5 - 30

no near competitors, good market (unfortunately) and a new management team seems ready to turn this company to be very profitable.

its gonna be unstoppable now.

You have to pay close attention to every slide on its most recent presentation.

Replacement sales increased by 75% in fiscal 2008 over 2007 and were the key driver of growth, masking the mediocre growth of sales of generators to new patients.

New patients sales are the key measurement of growth and penetration of the epilespy market. I would study, analyze and fully understand slide 11. De novo sales were flat year over year. The replacement sale cycle will drop in late fiscal 2009 and the company had better hope that there is a dramatic increase new patient sales.

Cyberonics's depression business is dead.

They have expected high profitability for upcoming quarters, and have just reported increased financials. Still looking for some financing but I think an overall good pick.

rated high; growing

under valued this teck will be need more and more

LN

Finally, cyberspace and electronics have combined to cure epilepsy! I have a chronic disorder, and the only cure is big gains on CYBX!

Cyberonics is a neuromodulation company engaged in designing, developing and bringing to market medical devices that provide Vagus Nerve Stimulation (VNS) Therapy, for the treatment of epilepsy, treatment-resistant depression (TRD) and other debilitating neurological or psychiatric diseases, and other disorders.

VNS Therapy consists of the electrical stimulation of the Vagus nerve with an implantable device. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool. In July 2005, FDA also approved the VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode.

Net sales for the thirteen weeks ended January 2007 decreased by $1.0 million, or 4%, primarily as a result of 5% decrease in unit sales volumes partially offset by 2% rise in sales price. However, Cyberonics will remain a company that is struggling commercially which is seen from its slower than expected revenue growth in depression sales, substantial market development expenses and inadequate reimbursement. Its epilepsy business has low prospects for future growth, as new patient sales have remained flat.

Recently the Centers for Medicare and Medicaid Services (CMS) posted a proposed National Coverage Determination (NCD) arguing that there is sufficient evidence to conclude that Vagus nerve stimulation is not a reasonable treatment of resistant depression. This decision is bad news for Cyberonics, as this means that the company cannot expect help from CMS to pay for post-approval studies, and the cost will be left on the shoulders of Cyberonics. All these factors sum up to Cyberonics being a poor investment proposition.

Far too much debt to beat the S

Will be taken over.